Literature DB >> 19667260

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

Leora Horn, William Pao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19667260      PMCID： PMC6955145          DOI： 10.1200/JCO.2009.23.6661

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  32 in total

1.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Authors:  Anna V Galkin; Jonathan S Melnick; Sungjoon Kim; Tami L Hood; Nanxin Li; Lintong Li; Gang Xia; Ruo Steensma; Greg Chopiuk; Jiqing Jiang; Yongqin Wan; Peter Ding; Yi Liu; Fangxian Sun; Peter G Schultz; Nathanael S Gray; Markus Warmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

2.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Authors:  David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

4.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

5.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

Authors:  Kentaro Inamura; Kengo Takeuchi; Yuki Togashi; Satoko Hatano; Hironori Ninomiya; Noriko Motoi; Ming-yon Mun; Yukinori Sakao; Sakae Okumura; Ken Nakagawa; Manabu Soda; Young Lim Choi; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Mod Pathol       Date:  2009-02-20       Impact factor: 7.842

6.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Authors:  Ultan McDermott; A John Iafrate; Nathanael S Gray; Toshi Shioda; Marie Classon; Shyamala Maheswaran; Wenjun Zhou; Hwan Geun Choi; Shannon L Smith; Lori Dowell; Lindsey E Ulkus; Georgiana Kuhlmann; Patricia Greninger; James G Christensen; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

Authors:  Isabelle Janoueix-Lerosey; Delphine Lequin; Laurence Brugières; Agnès Ribeiro; Loïc de Pontual; Valérie Combaret; Virginie Raynal; Alain Puisieux; Gudrun Schleiermacher; Gaëlle Pierron; Dominique Valteau-Couanet; Thierry Frebourg; Jean Michon; Stanislas Lyonnet; Jeanne Amiel; Olivier Delattre
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

9.  EML4-ALK fusion lung cancer: a rare acquired event.

Authors:  Sven Perner; Patrick L Wagner; Francesca Demichelis; Rohit Mehra; Christopher J Lafargue; Benjamin J Moss; Stefanie Arbogast; Alex Soltermann; Walter Weder; Thomas J Giordano; David G Beer; David S Rickman; Arul M Chinnaiyan; Holger Moch; Mark A Rubin
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

10.  EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.

Authors:  Y Fukuyoshi; H Inoue; Y Kita; T Utsunomiya; T Ishida; M Mori
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640
View more
  119 in total

1.  The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment.

Authors:  L M Ofiara; A Navasakulpong; N Ezer; A V Gonzalez
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

Review 2.  Targeted therapies for non-small cell lung cancer: an evolving landscape.

Authors:  Sumanta Kumar Pal; Robert A Figlin; Karen Reckamp
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

Review 3.  Molecular testing in lung cancer: the time is now.

Authors:  Haiying Cheng; Xunhai Xu; Daniel B Costa; Charles A Powell; Balazs Halmos
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

4.  Protein inhibitor of activated STAT3 expression in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Ilse Vlassenbroeck; Rosana Eisenberg; Afshin Dowlati
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

Review 5.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 6.  Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.

Authors:  Jason H Tang; David Chia
Journal:  Crit Rev Oncog       Date:  2015

Review 7.  Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  F Couñago; A Rodríguez; P Calvo; J Luna; J L Monroy; B Taboada; V Díaz; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2016-04-22       Impact factor: 3.405

Review 8.  [Molecular pathology of the lungs. New perspectives by next generation sequencing].

Authors:  C Vollbrecht; K König; L Heukamp; R Büttner; M Odenthal
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

Review 9.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493

10.  Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Authors:  Jim Sang; Jaime Acquaviva; Julie C Friedland; Donald L Smith; Manuel Sequeira; Chaohua Zhang; Qin Jiang; Liquan Xue; Christine M Lovly; John-Paul Jimenez; Alice T Shaw; Robert C Doebele; Suqin He; Richard C Bates; D Ross Camidge; Stephan W Morris; Iman El-Hariry; David A Proia
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.